This is a Medudy Master Series on prostate cancer.
This module highlights the key aspects of metastatic hormone-sensitive prostate cancer (mHSPC) and will be presented by Prof. Dr. Axel Merseburger, Director of the Department of Urology at the Lübeck Campus of the University Medical Center Schleswig-Holstein.
The course is divided into four parts: The first part deals with the epidemiology and staging of mHSPC. The second part is dedicated to the modern management and treatment options of mHSPC. The third part looks at the evidence and clinical relevance of double versus triple therapy, followed by a summary of the key messages on mHSPC. Finally, the fourth part provides an outlook on follow-up and the transition to the castration-resistant stage.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was created with the kind support of Johnson & Johnson, Astra Zeneca, Bayer, Astellas and AMGEN.
At the end of this training you will know:
- The epidemiology and staging of metastatic hormone-sensitive prostate cancer (mHSPC) and the classification according to risk and volume criteria.
- The modern management and treatment options of mHSPC, from current guideline recommendations to practical treatment decisions.
- The evidence and clinical relevance of double versus triple therapy in mHSPC.
- An outlook on the follow-up and the transition to the castration-resistant stage.
